drugset
drugset / Trial / NCT00607906

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

NCT00607906 ↗

Phase 1 Completed 36 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.

Timeline

Start
2007-11-16
Primary completion
2008-03-10
Completion
2008-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-756050 Small molecule 5 mg Oral
Subject SB-756050 Small molecule 15 mg Oral
Subject SB-756050 Small molecule 50 mg Oral
Subject SB-756050 Small molecule 100 mg Oral
Subject SB-756050 Small molecule 150 mg Oral
Subject SB-756050 Small molecule 200 mg Oral
Subject SB-756050 Small molecule 300 mg Oral
Subject SB-756050 Small molecule 400 mg Oral

Indications

type 2 diabetes mellitus